Frustrated by regulatory delays at FDA, biotech companies warm to user fees.
Gershon
D
D
D001709:Biotechnology / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics*